A former executive at companies like Syndax Pharmaceuticals, AstraZeneca and Pfizer has landed a new funding round for his latest venture.

Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer. All of ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging Hong Kong's biotech fundraising momentum is expected to extend into 2026 ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). The Silicon Valley-based venture capitalist announced $15 billion raised across ...

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year. Aided by a rebound in ...